International Congress on Hormonal Steroids and Hormones and Cancer The role of vitamin D and retinoids in controlling prostate cancer progression

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• 9-cis-retinoic acid but not 4-(hydroxyphenyl)retinamide inhibits prostate intraepithelial neoplasia in Noble rats.

  2002cited by this paper
• 25-Hydroxyvitamin D-1α-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer

  2002cited by this paper
• Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth.

  2002cited by this paper
• The case for early androgen deprivation: the data should not be ignored.

  2002cited by this paper
• Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer.

  2002cited by this paper
• Phase I trial of 1α-hydroxyvitamin D2 in patients with hormone refractory prostate cancer

  2002cited by this paper
• Degradation of RXRs influences sensitivity of rat osteosarcoma cells to the antiproliferative effects of calcitriol.

  2002cited by this paper
• Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer.

  2002cited by this paper
• An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet‐B radiation

  2002cited by this paper
• The G gamma / T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089.

  2002cited by this paper
• Prostatic intraepithelial neoplasia in mice with conditional disruption of the retinoid X receptor alpha allele in the prostate epithelium.

  2002cited by this paper
• Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens.

  2002cited by this paper
• Growth inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31.

  2001cited by this paper
• Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1.

  2001cited by this paper
• A Phase I trial of pulse calcitriol in patients with refractory malignancies

  2001cited by this paper
• The Role of Epigenetic Modifications in Retinoic Acid Receptor β2 Gene Expression in Human Prostate Cancers

  2001cited by this paper
• Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications.

  2001cited by this paper
• Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition.

  2001influential reference
• Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis.

  2001cited by this paper
• Antagonists of retinoic acid receptors (RARs) are potent growth inhibitors of prostate carcinoma cells

  2001cited by this paper
• Expression patterns of vitamin D receptor in human prostate

  2001cited by this paper
• Regulation of proliferation of prostate epithelial cells by 1,25-dihydroxyvitamin D3 is accompanied by an increase in insulin-like growth factor binding protein-3.

  2001cited by this paper
• The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer.

  2000cited by this paper
• Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)

  2000cited by this paper
• The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy.

  2000cited by this paper
• Effect of 13-cis-retinoic acid on serum prostate-specific antigen levels in patients with recurrent prostate cancer after radical prostatectomy.

  2000cited by this paper
• International trends and patterns of prostate cancer incidence and mortality

  2000cited by this paper
• 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.

  2000cited by this paper
• Immunohistochemical study of the receptors for retinoic acid in prostatic adenocarcinoma.

  2000cited by this paper
• 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration.

  2000cited by this paper
• 1α,25-Dihydroxyvitamin D3 Inhibits Prostate Cancer Cell Growth by Androgen-Dependent and Androgen-Independent Mechanisms.

  2000cited by this paper
• Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens.

  2000cited by this paper
• Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2.

  2000cited by this paper
• Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.

  1999cited by this paper
• Vitamin D in the prevention and treatment of prostate cancer.

  1999cited by this paper
• Synthetic retinoid CD437 induces S‐phase arrest and apoptosis in human prostate cancer cells LNCaP and PC‐3

  1999cited by this paper
• Biological determinants of cancer progression in men with prostate cancer.

  1999cited by this paper
• Activation of Rb and decline in androgen receptor protein precede retinoic acid–induced apoptosis in androgen‐dependent LNCaP cells and their androgen‐independent derivative

  1999cited by this paper
• An international evaluation of the cancer preventive potential of vitamin A.

  1999cited by this paper
• Novel 20‐epi‐vitamin D3 analog combined with 9‐cis‐retinoic acid markedly inhibits colony growth of prostate cancer cells

  1999cited by this paper
• Changes in tissue transglutaminase activity and expression during retinoic acid-induced growth arrest and apoptosis in primary cultures of human epithelial prostate cells.

  1999cited by this paper
• Soy, disease prevention, and prostate cancer.

  1999cited by this paper
• Mitogen-activated protein kinase inhibits 1,25-dihydroxyvitamin D3–dependent signal transduction by phosphorylating human retinoid X receptor α

  1999cited by this paper
• Influence of dietary calcium and vitamin D on diet-induced epithelial cell hyperproliferation in mice.

  1999cited by this paper
• Phase II study of all-trans retinoic acid administered intermittently for hormone refractory prostate cancer.

  1999cited by this paper
• Altered growth regulation and loss of response to retinoic acid accompany tumorigenic transformation of prostatic cells.

  1999cited by this paper
• Mitogen-activated protein kinase inhibits 1,25-dihydroxyvitamin D3-dependent signal transduction by phosphorylating human retinoid X receptor alpha.

  1999cited by this paper
• Vitamin D and Prostate Cancer

  1999cited by this paper
• Induction of Androgen Receptor by 1α,25-Dihydroxyvitamin D3 and 9-cis Retinoic Acid in LNCaP Human Prostate Cancer Cells.

  1999cited by this paper
• Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.

  1999cited by this paper
• A selective retinoid with high activity against an androgen‐resistant prostate cancer cell type

  1999cited by this paper
• Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid.

  1999cited by this paper
• Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States)

  1998cited by this paper
• Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol)

  1998cited by this paper
• Antiproliferative Effect of 1α,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation.

  1998cited by this paper
• Vitamin D and Prostate Cancer: Biologic Interactions and Clinical Potentials

  1998cited by this paper
• Calcium and fructose intake in relation to risk of prostate cancer.

  1998cited by this paper
• Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.

  1998cited by this paper
• Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3.

  1998cited by this paper
• Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate.

  1998cited by this paper
• Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade

  1998cited by this paper
• Vitamin D receptor expression as a predictive marker of biological behavior in human colorectal cancer.

  1998cited by this paper
• Expression of Retinoic Acid Receptor-β Sensitizes Prostate Cancer Cells to Growth Inhibition Mediated by Combinations of Retinoids and a 19-nor Hexafluoride Vitamin D3 Analog.

  1998cited by this paper
• A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis

  1997cited by this paper
• Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines.

  1997cited by this paper
• Comparison of ras activation in prostate carcinoma in Japanese and American men

  1997cited by this paper
• Response of cell growth and retinoic acid receptor expression to retinoic acid in neoplastic and non‐neoplastic prostate cell lines

  1997cited by this paper
• 1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells.

  1997cited by this paper
• Effects of retinoid X receptor‐selective ligands on profileration of prostate cancer cells

  1997cited by this paper
• The natural history of clinical prostate carcinoma

  1997cited by this paper
• Vitamin D metabolism: the effects of aging.

  1997cited by this paper
• Effects of fenretinide (4‐HPR) on prostate LNCaP cell growth, apoptosis, and prostate‐specific gene expression

  1997cited by this paper
• Effect of retinoic acid on prostatic development

  1997cited by this paper
• 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1.

  1997cited by this paper
• Retinoids in cancer chemoprevention

  1996cited by this paper
• Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway.

  1996cited by this paper
• Abnormal level of retinoic acid in prostate cancer tissues.

  1996cited by this paper
• Circulating vitamin D metabolites in relation to subsequent development of prostate cancer.

  1996cited by this paper
• Simian virus 40-, but not human papillomavirus-, transformation of prostatic epithelial cells results in loss of growth-inhibition by 1,25-dihydroxyvitamin D-3.

  1996cited by this paper
• The role of vitamin D in normal prostate growth and differentiation.

  1996cited by this paper
• Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States)

  1995cited by this paper
• Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid.

  1995cited by this paper
• In vitro anti-invasive effects of N-(4-hydroxyphenyl)-retinamide on human prostatic adenocarcinoma.

  1995cited by this paper
• Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer.

  1995cited by this paper
• Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC‐3

  1995cited by this paper
• The nuclear receptor superfamily: the second decade.

  1995cited by this paper
• Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines.

  1995cited by this paper
• Suramin, hydrocortisone, and retinoic acid modify inhibitory effects of 1,25-dihydroxyvitamin D(3) on prostatic epithelial cells.

  1995cited by this paper
• Inhibition of tumorigenic potential and prostate‐specific antigen expression in LNCaP human prostate cancer cell line by 13‐cis‐retinoic acid

  1994cited by this paper
• N‐(4‐hydroxyphenyl) retinamide induces cell cycle specific growth inhibition in PC3 cells

  1994cited by this paper
• Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells.

  1994cited by this paper
• Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells.

  1993cited by this paper
• Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells

  1993cited by this paper
• The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients.

  1993cited by this paper
• Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.

  1992cited by this paper
• Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling

  1992cited by this paper
• Microcarcinoma in the prostate: its association with duct-acinar dysplasia.

  1991cited by this paper
• Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis).

  1990cited by this paper
• Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis).

  1990cited by this paper
• Intraductal dysplasia: a premalignant lesion of the prostate.

  1986cited by this paper

• Occupational exposure to solar ultraviolet B radiation and risk of prostate cancer in Danish men.

  2022cites this paper
• Nutritional supplementation of the pharmacotherapy of prostate diseases

  2021cites this paper
• Oxidative Stress, Diet and Prostate Cancer

  2020cites this paper
• Impact of oxidative stress SNPs and dietary antioxidant quality score on prostate cancer

  2020cites this paper
• Serum Retinol and Risk of Overall and Site-Specific Cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study.

  2019cites this paper
• Metabolomic Profiling of Serum Retinol in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study

  2017cites this paper
• Vitamins, metabolomics, and prostate cancer

  2017cites this paper
• Vitamin D [25(OH)D] Deficiency Patients in Prostate Cancer in Latvia

  2017cites this paper
• Connexins and Cadherin Crosstalk in the Pathogenesis of Prostate Cancer

  2015cites this paper
• Prevention of prostate cancer with vitamins - current perspectives.

  2014cites this paper
• Vitamin D3 Regulates the Formation and Degradation of Gap Junctions in Androgen-Responsive Human Prostate Cancer Cells

  2014cites this paper
• Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case–control study

  2014cites this paper
• Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade

  2012cites this paper
• Prostate cancer and metabolic syndrome: is there a link?

  2012cites this paper
• The induction of Guerin’s carcinoma cytochrome P450 hydroxylase activity by retinoids

  2011cites this paper
• Psoriasis and Other Skin Diseases

  2011cites this paper
• Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.

  2010cites this paper
• [Secondary hyperparathyroidism in advanced prostate cancer].

  2010cites this paper
• Serum Retinol and Prostate Cancer Risk: a Nested Case-Control Study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

  2009cites this paper
• 1,25(OH)2D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells.

  2009cites this paper
• Life course sun exposure and risk of prostate cancer: Population‐based nested case‐control study and meta‐analysis

  2009cites this paper
• Dairy product consumption and the risk of prostate cancer

  2009cites this paper
• 1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells.

  2009cites this paper
• Calcium intake and vitamin D metabolism and action, in healthy conditions and in prostate cancer.

  2007cites this paper
• Interaction of Factors Related to the Metabolic Syndrome and Vitamin D on Risk of Prostate Cancer

  2007cites this paper
• Role of oncoprotein growth factor independent-1 (GFI1) in repression of 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1): a comparative analysis in human prostate cancer and kidney cells.

  2007cites this paper
• Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol)

  2006cites this paper
• CHAPTER 104 – Inhibition of Benign Prostatic Hyperplasia by Vitamin D Receptor Ligands

  2005cites this paper
• Identification of growth factor independent-1 (GFI1) as a repressor of 25-hydroxyvitamin D 1-alpha hydroxylase (CYP27B1) gene expression in human prostate cancer cells.

  2005cites this paper
• CHAPTER 94 – Vitamin D and Prostate Cancer

  2005cites this paper
• Clinical trials involving vitamin D analogs in prostate cancer.

  2005cites this paper
• Use of multivitamins and prostate cancer mortality in a large cohort of US men

  2005cites this paper
• Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells

  2004cites this paper
• Geographic variation of prostate cancer mortality rates in the United States: Implications for prostate cancer risk related to vitamin D

  2004cites this paper
• Metabolism of 25‐hydroxyvitamin D3 may explain the u‐shaped risk curve for prostate cancer

  2004cites this paper